Segment Information

6 Months Ended

Jun. 30, 2013

Segment Information

Segment Information

13. Segment Information

We currently operate as one operating segment. However, our chief operating decision makers regularly review revenues, cost of revenues and gross profit data as a primary measure of performance for each of our three commercial products.

Revenues, cost of revenues and gross profit for each of our commercial products were as follows (in thousands):

	Three Months Ended June 30,
2013	Remodulin		Tyvaso		Adcirca		Total
Revenues	$	124,311	$	109,458	$	43,726	$	277,495
Cost of revenues	13,484		16,097		2,739		32,320
Gross profit	$	110,827	$	93,361	$	40,987	$	245,175
2012
Revenues	$	110,398	$	81,210	$	30,224	$	221,832
Cost of revenues	16,645		11,079		1,909		29,633
Gross profit	$	93,753	$	70,131	$	28,315	$	192,199

	Six Months Ended June 30,
2013	Remodulin		Tyvaso		Adcirca		Total
Revenues	$	238,992	$	204,103	$	77,546	$	520,641
Cost of revenues	26,890		29,880		4,863		61,633
Gross profit	$	212,102	$	174,223	$	72,683	$	459,008
2012
Revenues	$	220,944	$	151,276	$	52,555	$	424,775
Cost of revenues	29,994		20,277		3,393		53,664
Gross profit	$	190,950	$	130,999	$	49,162	$	371,111

For the three-month periods ended June 30, 2013 and 2012, net revenues from our three U.S.-based distributors represented 77 percent and 78 percent, respectively, of our total net operating revenues.

For the six-month periods ended June 30, 2013 and 2012, net revenues from our three U.S.-based distributors represented 77 percent and 80 percent, respectively, of our total net operating revenues.